日本消化性潰瘍薬市場の規模、シェア、競争環境、トレンド分析レポート：薬剤タイプ別（プロトンポンプ阻害薬（PPI）、H2拮抗薬、抗生物質、その他）、潰瘍タイプ別（胃炎、胃潰瘍、十二指腸潰瘍、胃食道逆流症（GERD））：2024年から2032年までの機会分析および業界予測
レポートID : ROJP1024289 |
発行日 : 2024年10月 |
フォーマット : 
: 
: 
無料サンプル
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
Japan Peptic Ulcer Drugs Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Drug Type(Proton Pump Inhibitors(PPI), H2 Antagonists, Antibiotics, and Others)
4.2.2. By Ulcer Type (Gastitis, Gastric Ulcer, Duodenal Ulcer, Gastroesophageal Reflux Disease (GERD))
4.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
4.3. Product Market Map
5. Japan Proton Pump Inhibitors(PPI) Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Ulcer Type
5.2.2. By Distribution Channel
6. Japan H2 Antagonists Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Ulcer Type
6.2.2. By Distribution Channel
7. Japan Antibiotics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Ulcer Type
7.2.2. By Distribution Channel
8. Market Dynamics
8.1. Drivers
8.2. Challenges
9. Market Trends & Developments
9.1. Research & Development
9.2. Product launch
9.3. Merger & Acquisition
10. Policy and Regulatory Landscape
11. Japan Peptic Ulcer Drugs Market: SWOT Analysis
12. Porter’s Five Forces Analysis
13. PESTLE Analysis
14. Competitive Landscape
14.1. Business Overview
14.2. Product Offerings
14.3. Recent Developments
14.4. Financials (In Case of Listed Companies)
14.5. Key Personnel
14.5.1. Takeda Pharmaceuticals Company limited.
14.5.2. AstraZeneca
14.5.3. Novartis Pharmaceutical corporation
14.5.4. Pfizer limited.
14.5.5. GlaxoSmithKline pharmaceuticals ltd
14.5.6. Mylan pharmaceutical inc.
15. Strategic Recommendations
16. About the Publisher & Disclaimer
